Literature DB >> 21641143

Single-dose ziprasidone associated with QT interval prolongation.

Joanne C Witsil1, Michele Zell-Kanter, Mark B Mycyk.   

Abstract

Ziprasidone has been rarely associated with QT prolongation especially in patients (1) with no underlying cardiac or metabolic disorders, (2) who are receiving no concomitant medications known to prolong the QT interval, and (3) whom therapy is being initiated at a low dose. We report a 47-year-old patient who was agitated with suicidal ideation. He had a history of cocaine use, the last time being 72 hours before emergency department (ED) presentation. His electrocardiogram (ECG) on arrival in the ED showed a QT of 484 milliseconds and a QTc of 475 milliseconds with a pulse of 58 beats per minute. The patient was given 20 mg intramuscular (IM) ziprasidone for agitation. He reported feeling palpitations and weakness 45 minutes after receiving ziprasidone. His QT interval was prolonged on ECG and returned to baseline after 72 hours. Clinicians should consider obtaining an ECG before ziprasidone administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21641143     DOI: 10.1016/j.ajem.2011.03.019

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

Review 1.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

Review 2.  Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.

Authors:  Eiji Kirino
Journal:  Clin Med Insights Pediatr       Date:  2014-05-25

3.  QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis.

Authors:  Xian-Bin Li; Yi-Lang Tang; Wei Zheng; Chuan-Yue Wang; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2014-11-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.